CSIMarket
 


Exelixis Inc   (EXEL)
Other Ticker:  
 

Exelixis Inc 's Long Term Debt to Equity

EXEL's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


In the forth quarter 2023 Exelixis Inc did not have Long Term Debt.

Within Biotechnology & Pharmaceuticals industry Exelixis Inc achieved the lowest Long Term Debt to Equity in the forth quarter 2023. While total ranking remained the same in the forth quarter 2023 compared to the previous quarter at no. .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt EXEL´s has?
What is the structure of EXEL´s Equity?


EXEL Long Term Debt to Equity (Dec 29 2023)
IV. Quarter
(Sep 29 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 30 2022)
IV. Quarter
Y / Y Equity Change -9.02 % -5.77 % 5.72 % 11.39 % 12.57 %
Y / Y Long Term Debt Change - - - - -
Long Term Debt to Equity MRQ - - - - -
EXEL's Total Ranking # # # # #
Seq. Equity Change -3.57 % -7.13 % -1.06 % 2.68 % -0.12 %
Seq. Long Term Debt Change - - - - -



Long Term Debt to Equity forth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall Market #


Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Exelixis Inc 's Equity $ 2,264 Millions Visit EXEL's Balance sheet
Exelixis Inc 's Long Term Debt $ 0 Millions Visit EXEL's Balance sheet
Source of EXEL's Sales Visit EXEL's Sales by Geography


Cumulative Exelixis Inc 's Long Term Debt to Equity

EXEL's Long Term Debt to Equity for the trailling 12 Months

EXEL Long Term Debt to Equity

(Dec 29 2023)
IV. Quarter
(Sep 29 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 30 2022)
IV. Quarter
Y / Y Equity TTM Growth -9.02 % -5.77 % 5.72 % 11.39 % 12.57 %
Y / Y Long Term Debt TTM Growth - - - - -
Long Term Debt to Equity TTM - - - - -
Total Ranking TTM
Seq. Equity TTM Growth -3.57 % -7.13 % -1.06 % 2.68 % -0.12 %
Seq. Long Term Debt TTM Growth - - - - -


On the trailing twelve months basis During the twelve months ending IV Quarter 2023 Exelixis Inc did not have Long Term Debt .
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry EXEL recorded the lowest Long Term Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 0.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt EXEL´s has?
What is the structure of EXEL´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Within the Market #


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Long Term Debt to Equity in the quarter ending Dec 29 2023, within Biotechnology & Pharmaceuticals Industry Long Term Debt to EquityDec 29 2023 MRQ Long Term DebtDec 29 2023 MRQ Equity

Date modified: 2024-02-06T23:42:01+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com